NCT02026505View on ClinicalTrials.gov

Evaluation of Cardiotoxic Effects of Bortezomib

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

March 1, 2019

Conditions
Multiple MyelomaHeart Failure, SystolicCardiotoxins
Interventions
DRUG

Bortezomib

All Listed Sponsors
collaborator

Millennium: The Takeda Oncology Company

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT02026505 - Evaluation of Cardiotoxic Effects of Bortezomib | Biotech Hunter | Biotech Hunter